Transfusion Requirements in Surgical Oncology Patients A Prospective, Randomized Controlled Trial

Imagem de Miniatura
Arquivos
art_ALMEIDA_Transfusion_Requirements_in_Surgical_Oncology_Patients_A_Prospective_2015.PDF (388.36 KB)
Citações na Scopus
156
Tipo de produção
article
Data de publicação
2015
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Autores
VINCENT, Jean-Louis
Citação
ANESTHESIOLOGY, v.122, n.1, p.29-38, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Several studies have indicated that a restrictive erythrocyte transfusion strategy is as safe as a liberal one in critically ill patients, but there is no clear evidence to support the superiority of any perioperative transfusion strategy in patients with cancer. Methods: In a randomized, controlled, parallel-group, double-blind (patients and outcome assessors) superiority trial in the intensive care unit of a tertiary oncology hospital, the authors evaluated whether a restrictive strategy of erythrocyte transfusion (transfusion when hemoglobin concentration <7 g/dl) was superior to a liberal one (transfusion when hemoglobin concentration <9 g/dl) for reducing mortality and severe clinical complications among patients having major cancer surgery. All adult patients with cancer having major abdominal surgery who required postoperative intensive care were included and randomly allocated to treatment with the liberal or the restrictive erythrocyte transfusion strategy. The primary outcome was a composite endpoint of mortality and morbidity. Results: A total of 198 patients were included as follows: 101 in the restrictive group and 97 in the liberal group. The primary composite endpoint occurred in 19.6% (95% CI, 12.9 to 28.6%) of patients in the liberal-strategy group and in 35.6% (27.0 to 45.4%) of patients in the restrictive-strategy group (P = 0.012). Compared with the restrictive strategy, the liberal transfusion strategy was associated with an absolute risk reduction for the composite outcome of 16% (3.8 to 28.2%) and a number needed to treat of 6.2 (3.5 to 26.5). Conclusion: A liberal erythrocyte transfusion strategy with a hemoglobin trigger of 9 g/dl was associated with fewer major postoperative complications in patients having major cancer surgery compared with a restrictive strategy.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/9648
Referências
  1. Acheson AG, 2012, ANN SURG, V256, P235, DOI 10.1097/SLA.0b013e31825b35d5
  2. Amato A, 2006, COCHRANE DB SYST REV, DOI 10.1002/1465158.CD005033.pub2
  3. Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872
  4. BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818
  5. Carson JL, 2011, NEW ENGL J MED, V365, P2453, DOI 10.1056/NEJMoa1012452
  6. Carson JL, 1996, LANCET, V348, P1055, DOI 10.1016/S0140-6736(96)04330-9
  7. Carson JL, 2002, TRANSFUSION, V42, P812, DOI 10.1046/j.1537-2995.2002.00123.x
  8. CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
  9. Dicato M, 2010, ANN ONCOL, V21, P167, DOI 10.1093/annonc/mdq284
  10. Flancbaum L, 1998, J CARDIOTHOR VASC AN, V12, P3, DOI 10.1016/S1053-0770(98)90047-7
  11. Hajjar LA, 2010, JAMA-J AM MED ASSOC, V304, P1559, DOI 10.1001/jama.2010.1446
  12. Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601
  13. Jhanji S, 2010, CRIT CARE, V14, DOI 10.1186/cc9220
  14. Koch M, 2011, ANN SURG ONCOL, V18, P1404, DOI 10.1245/s10434-010-1453-x
  15. Law S, 2004, ANN SURG, V240, P791, DOI 10.1097/01.sla.0000143123.245561c
  16. Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B
  17. Lobo SMA, 2000, CRIT CARE MED, V28, P3396, DOI 10.1097/00003246-200010000-00003
  18. Masoomi H, 2012, J AM COLL SURGEONS, V215, P255, DOI 10.1016/j.jamcollsurg.2012.04.019
  19. OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014
  20. Park DW, 2012, CRIT CARE MED, V40, P3140, DOI 10.1097/CCM.0b013e3182657b75
  21. Pearse R, 2005, CRIT CARE, V9, pR694, DOI 10.1186/cc3888
  22. Pearse R, 2005, CRIT CARE, V9, pR687, DOI 10.1186/cc3887
  23. Pearse RM, 2012, LANCET, V380, P1059, DOI 10.1016/S0140-6736(12)61148-9
  24. Pearse RM, 2008, CRIT CARE MED, V36, P1323, DOI [10.1097/CCM.0b013e31816a091b, 10.1097/CCM.0b013e31816091b]
  25. Sakr Y, 2010, CRIT CARE, V14, DOI 10.1186/cc9026
  26. Sakr Y, 2007, CRIT CARE MED, V35, P1639, DOI 10.1097/01.CCM.0000269936.73788.32
  27. SCHAG CC, 1984, J CLIN ONCOL, V2, P187
  28. Soares M, 2010, CRIT CARE MED, V38, P9, DOI 10.1097/CCM.0b013e3181c0349e
  29. Thygesen K, 2007, J AM COLL CARDIOL, V50, P2173, DOI 10.1016/j.jacc.2007.09.011
  30. Vamvakas EC, 2001, BLOOD, V97, P1180, DOI 10.1182/blood.V97.5.1180
  31. Weber RS, 2008, ANN SURG ONCOL, V15, P34, DOI 10.1245/s10434-007-9502-9
  32. Weinberg JA, 2012, SHOCK, V37, P276, DOI 10.1097/SHK.0b013e318241b739
  33. Wu WC, 2007, JAMA-J AM MED ASSOC, V297, P2481, DOI 10.1001/jama.297.22.2481

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Carregar mais